Pacira BioSciences比起收入估算, 获得了“买入”评级, 以及先进的非类阿片止痛治疗。 Pacira BioSciences beat earnings estimates, gained a "buy" rating, and advanced non-opioid pain treatments.

Pacira BioSciences(PCRX)得到Endham & Company的“买”评级, 标价为30.00美元, Pacira BioSciences (PCRX) received a "buy" rating from Needham & Company with a $30.00 price target, citing potential 15.3% upside. 该公司报告第四季度每股收益为0.70美元,超过预期的0.05美元,收入同比增长6.5%,达到1.79亿美元,尽管略低于共识. The company reported fourth-quarter earnings of $0.70 per share, beating estimates by $0.05, with revenue up 6.5% year-over-year to $179.52 million, though slightly below consensus. 过去90天内幕出售了34 336股股票,价值约851 868美元,将内幕所有权减少到6.4%。 Insiders sold 34,336 shares valued at about $851,868 in the past 90 days, reducing insider ownership to 6.4%. 该股票的市场上限为11.2亿美元,52周范围为19.81美元至27.64美元,PE比率为57.82美元。 The stock has a market cap of $1.12 billion, a 52-week range of $19.81 to $27.64, and a PE ratio of 57.82. 分析师维持一种混杂的共识,有“稳住”评级和28.20美元目标,而公司则推行非类阿片止痛疗法,包括EXPAREL和膝部骨髓炎基因疗法。 Analysts maintain a mixed consensus, with a "hold" rating and a $28.20 target, while the company advances non-opioid pain therapies including EXPAREL and a gene therapy for knee osteoarthritis.